Recently, de Castro et al. [68] and Aquino et al. [66] demonstrated that the combination of an NF-κB inhibitor and a selective fatty acid synthase (FASN) inhibitor, respectively, enhanced the chemosensitivity of cisplatin in an in vitro model resistant to cisplatin treatment in HNSCC. This evidence concerns the gene FASN and head and neck squamous cell carcinoma.